1. 157P Phase I expansion of IMC-C103C, a MAGE-A4×CD3 ImmTAC bispecific protein, in ovarian carcinoma. (December 2022) Authors: Sweis, R.; Garralda, E.; Saavedra Santa Gadea, O.; Moore, K.N.; Davar, D.; Hamid, O.; Segal, N.H.; Evans, T.R.J.; Dar, M.; Yuan, Y.; Collins, L.; Kirk, P.B.; Karakuzu, O.; Lopez, J.S.; Melero, I. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 200MO Anti–IL-8 BMS-986253 + nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with advanced cancer: Update of initial phase I results. (December 2022) Authors: Simonelli, M.; Calvo, E.; Davar, D.; Richards, D.; Gutierrez, M.; Moreno Garcia, V.; Marron, T.; Rottey, S.; Orcurto, A.; Renouf, D.J.; Joerger, M.; Barriga Falcon, S.; Fan, J.; Gibson, E.; Chakraborty, D.; Arora, V.; Melero, I. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗